Biotech PR: What It Is and 6 Agencies Worth Knowing
Biotech PR is the communications work that builds scientific, regulatory and financial credibility for companies developing drugs, gene therapies, diagnostics and devices. It serves investors, regulators, clinicians, patients and partners at once, under SEC disclosure rules and FDA limits on promotion. Specialist agencies such as LifeSci Communications, LaVoieHealthScience, Russo Partners, Spectrum Science and Real Chemistry run much of it.
Updated October 18, 2026.
What is biotech PR?
Biotech PR is the discipline of communicating a company's science, clinical progress and business position to the audiences that decide its future. Because a biotech product can take years to reach market, much of the work is sustaining confidence between milestones, such as trial readouts, financings and regulatory decisions.
Who does biotech PR talk to?
Biotech PR talks to five audiences, and each one needs different information through different channels.
Audience
What they need
Typical channel
Investors and analysts
Clinical milestones, financings and pipeline updates
Earnings calls, investor conferences such as the J.P. Morgan Healthcare Conference in January
Regulators
Accurate and timely disclosure
Company filings and the FDA review process
Clinicians
Trial data and scientific context
Peer-reviewed journals and meetings such as ASCO and ASH
Patients and advocacy groups
Clear, ethical information about conditions and trials
Advocacy partnerships and patient communities
Partners and acquirers
Evidence the science and the team are credible
Joint announcements and business press
How do SEC and FDA rules shape biotech PR?
SEC and FDA rules limit what a biotech company can say and when. Public companies must disclose material information fairly under the SEC's Regulation FD, which requires that it reach all investors at the same time. The FDA restricts promotion of prescription drugs: promotional claims must be balanced with risk information, and companies cannot promote unapproved uses.
For that reason, a communications team coordinates with legal, regulatory affairs and clinical operations before each announcement. A statement that would be routine in technology PR can create a compliance problem in biotech.
How is biotech PR different from technology PR?
Time horizon: development runs for years, from preclinical work through trials and approval, so communications has to hold interest across long gaps.
Regulated claims: what a company may say about a product is limited by regulators, not only by brand preference.
Trust stakes: patients, doctors and investors commit health, prescribing decisions and capital based on what the company says.
Scientific publication: peer-reviewed journals and medical meetings are part of the credibility record in a way they are not for most technology brands.
What are the main functions of a biotech PR team?
Investor and analyst communications around financings, earnings and pipeline updates.
Regulatory milestone communications, including advisory committee meetings, approvals and Complete Response Letters.
Scientific and medical communications, including publications, conference programs and relationships with key opinion leaders.
Clinical trial communications, from trial launch through interim analyses and primary endpoint readouts.
Patient advocacy and community engagement.
Corporate, M&A and crisis communications.
Visibility in AI answers, since clinicians, patients and investors increasingly research companies in ChatGPT, Claude, Perplexity, Gemini and Google AI Overviews.
Which agencies run biotech PR?
Six agencies are worth knowing, grouped by the type of work they suit. This is a guide to agency types, not a ranking.
Brands that want AI answer visibility measured alongside earned media
Disclosure: Everything-PR News, LLC, published by a shared interest group, and 5W share a common ownership connection. The ranked comparison of 20 healthcare and biotech firms is in Best Healthcare and Biotech PR Agencies in 2026.
How should a biotech company choose an agency by stage?
A biotech company should match the agency type to its stage, because the communications job changes at each one.
Development-stage and pre-IPO: choose a specialist that handles investor relations, since clinical milestones and financings drive the work.
Late-stage with regulatory milestones: choose a science-first independent that can pair compliant messaging with media relations around FDA actions.
Commercial-stage launch: choose a healthcare network with prescriber, payer and patient advocacy reach.
Any stage competing in AI answers: add a capability that tracks how often the company is named in AI engines.
What mistakes recur in biotech communications?
Five mistakes recur in biotech communications failures.
Overpromising at clinical readouts, when the positioning does not survive later regulatory review or peer analysis.
Founder-led storytelling that runs ahead of the science. Theranos dissolved in 2018, and a federal jury convicted founder Elizabeth Holmes of fraud in January 2022. EPR covers the pattern in health PR failures.
No plan for safety signals, so the first communication about a drug safety issue is made under pressure. The classic product-safety case is the Tylenol crisis of 1982.
Patient advocacy that reads as marketing instead of a long-term relationship.
Ignoring AI answers, which clinicians and patients increasingly use to research companies.
How is biotech PR measured?
Biotech PR is measured through investor and analyst sentiment, engagement at scientific conferences, pickup of peer-reviewed publications, share of voice in medical and business press, clinician awareness, and how often the company is named in AI answers. Teams track each against a baseline set before a milestone so the effect of the communications can be seen.
How much does biotech PR cost?
EPR estimates full-service biotech retainers at $20,000 to $60,000 per month, with IPO and milestone work priced as projects on top. The figure comes from EPR's pricing analysis in Best Healthcare and Biotech PR Agencies in 2026 and is an estimate, not a published rate card.
LifeSci Communications, LaVoieHealthScience and Russo Partners are life sciences specialists, Spectrum Science is a science-first independent, Real Chemistry is a healthcare commercialization network, and 5W is a PR, creative and GEO agency. The right choice depends on the company's stage.
What is the difference between biotech PR and pharmaceutical PR?
Biotech PR usually serves development-stage and commercial biotechnology companies, while pharmaceutical PR usually serves the large drugmakers. Both operate under FDA constraints and similar crisis risks, but biotech work involves more pre-commercial communication around trials and financings. EPR covers the large-company side in its pharma public relations guide.
How does biotech PR work with the FDA?
Biotech PR does not communicate with the FDA on the company's behalf. It works within FDA rules on promotion, such as balancing claims with risk information and avoiding promotion of unapproved uses, and it coordinates with regulatory affairs before announcing FDA actions.
What is a key opinion leader?
A key opinion leader is a physician or researcher whose standing in a therapeutic area influences clinical practice and peer opinion. Biotech companies usually manage those relationships through medical affairs, not commercial communications.
How much does biotech PR cost?
EPR estimates $20,000 to $60,000 per month for full-service retainers, with IPO and milestone work priced separately. Ask each agency for a written quote.
How is biotech PR measured?
Through investor sentiment, conference engagement, publication pickup, share of voice in medical and business press, clinician awareness and presence in AI answers.
Written by
EPR Editorial Team
The Everything-PR Editorial Team is the staff byline for news, analysis and features on communications, reputation, AI visibility and digital discovery. Everything-PR has published since 2009. AI tools assist with research and drafting, and every article is reviewed by a human editor before publication. Coverage follows the Editorial Policy, and substantive corrections are noted on the article under the Corrections Policy.
